Game-Changer for Lymphoma Treatment!

Big news for mantle cell lymphoma patients: the EU just approved a new combo therapy with acalabrutinib, bendamustine, and rituximab as a first-line treatment! This means older patients who can’t get stem cell transplants now have a shot at better outcomes—16+ months longer progression-free survival compared to standard chemo. The trial showed higher response rates too. It’s not a cure, but it’s a much-needed win for a tough cancer. Science for the win! #Lymphoma #CancerResearch #MedicalBreakthrough #HealthcareNews #Health